|
Market Data
Ginkgo Bioworks Holdings Inc.
Ginkgo Bioworks utilizes a cell programming platform to engineer organisms for various industries. The company's core business centers on providing research and development solutions, as well as specialized tools, to facilitate the creation and commercialization of engineered organisms and their resulting products. These offerings include functional genomics, AI models, and automation systems, catering to diverse sectors such as pharmaceuticals, agriculture, and consumer goods. Furthermore, Ginkgo Bioworks provides biosecurity services through its Canopy and Horizon platforms, which offer biomonitoring and digital surveillance capabilities to detect and analyze potential biothreats. Founded in 2008, Ginkgo Bioworks is headquartered in Boston, Massachusetts, and aims to provide innovative solutions to a wide range of industries.
DNA is currently trading at $8.02, giving Ginkgo Bioworks Holdings Inc. a market cap of 0.49B. Today's range spans $7.82–$8.30, with shares opening at $8.29 and moving down $0.01 (0.1%) from the prior close. DailyIQ's technical score sits at 68/100 (BUY) with a news sentiment reading of 0/100.
Over the past year DNA has traded between $5.37 and $17.58 - the current price is +49.3% off the 52-week low and -54.4% from the high. 12 analysts cover the stock with a Sell consensus and a mean 12-month target of $10.00 (range $9.00–$12.00), implying upside of +24.7%.
Small-cap Healthcare names with bullish setups like DNA - 68/100, BUY, sentiment bearish at 0/100, price $8.02 (in the lower half of its 52-week range) - are where the highest-conviction active managers look when they want exposure to a sector theme without paying the premium of larger-cap proxies. At 0.49B in market cap, the risk is higher, but so is the potential return relative to the benchmark. Annual range: $5.37–$17.58.
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'25 | - | - | - |
| Q3'25 | $-1.24 | $-1.45 | -16.9% |
| Q2'25 | $-1.57 | $-1.10 | +29.8% |
| Q1'25 | $-1.77 | $-1.68 | +5.1% |
| Q4'24 | $-1.30 | $-1.21 | +6.7% |
| Qtr | Est | Actual | +/− |
|---|---|---|---|
| Q4'25 | $43M | - | - |
| Q3'25 | - | $39M | - |
| Q2'25 | - | $50M | - |
| Q1'25 | - | $48M | - |
| Q4'24 | - | $44M | - |
Sentiment gathered from recent headlines
Most recent articles, ranked by recency (click to expand).